Adial gets US patent linked to AD04, diagnostic test for alcohol/opioid use disorder

Jun. 14, 2022 11:54 AM ETAdial Pharmaceuticals, Inc. (ADIL)By: Ravikash, SA News Editor

IP, Intellectual Property Patent Concept

Olivier Le Moal/iStock via Getty Images

  • Adial Pharmaceuticals (NASDAQ:ADIL) said June 14 that the U.S. Patent and Trademark Office issued a patent on June 7 covering the use of its genetic diagnostic panel in combination with lead product AD04 to treat alcohol use disorder (AUD) and opioid use disorder (OUD).
  • The company said the patent 11,351,154 expands coverage of previously issued patents to include the measurement of the genetic biomarkers for all of the targeted genotypes using its proprietary diagnostic test.
  • "This latest patent covering the use of AD04 as a potential treatment for AUD and OUD, combining all five distinct genetic biomarkers, is a critical component of our broader strategy to build a robust moat of patents around AD04," said Adial's CEO William Stilley.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.